{"id":"https://genegraph.clinicalgenome.org/r/6926b894-073d-4f7a-948f-d9720f00871cv1.0","type":"EvidenceStrengthAssertion","dc:description":"MPI was first reported in relation to autosomal recessive congenital disorder of glycosylation in 1998 (Niehues et al., PMID 9525984). Fourteen variants (missense, nonsense, frameshift, splice site) that have been reported in 10 probands in 7 publications (PMIDs 9525984, 10980531, 9585601, 11350186, 17945525, 33204592, 33098580) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts) has been reached. Patients have a range of symptoms, including protein losing enteropathy, gastrointestinal involvement, hepatomegaly, hepatic fibrosis, and hypoglycemia. The disease mechanism appears to be biallelic loss of function. Heterozygous carriers are reportedly unaffected. This gene-disease relationship is also supported by the biochemical function of MPI, which converts fructose-6-phosphate into mannose-6-phosphate, providing the necessary mannose-6-phosphate for glycosylation (PMID 9525984). Animal models deficient in MPI, including mouse and zebrafish, have defects in N-glycosylation consistent with patients with MPI-CDG (PMIDs 22899857, 24474243). In vitro assays in patient cells also support an N-glycosylation defect (PMID 22496445). In summary, there is definitive evidence supporting the relationship between MPI and autosomal recessive congenital disorder of glycosylation. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Congenital Disorders of Glycosylation Gene Curation Expert Panel on December 20, 2023 (SOP version 10). Additional contributions to this curation were made by UNC Biocuration Core and Counsyl.\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/6926b894-073d-4f7a-948f-d9720f00871c","GCISnapshot":"https://genegraph.clinicalgenome.org/r/a6c880b8-c9fc-453b-8975-236a97047192","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/a6c880b8-c9fc-453b-8975-236a97047192_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2023-12-26T14:37:36.155Z","role":"Publisher"},{"agent":"https://genegraph.clinicalgenome.org/agent/10018","role":"SecondaryContributor"},{"id":"https://genegraph.clinicalgenome.org/r/a6c880b8-c9fc-453b-8975-236a97047192_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2023-12-20T17:00:00.000Z","role":"Approver"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a6c880b8-c9fc-453b-8975-236a97047192_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f50493b8-3463-4db8-b2de-decc03c42d54_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/62a29060-c957-4b0c-a329-3784857c8043","type":"EvidenceLine","dc:description":"Absence of MPI activity in patient cells","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/62a29060-c957-4b0c-a329-3784857c8043_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33098580","allele":{"id":"https://genegraph.clinicalgenome.org/r/cf2723e0-24bb-462a-a11c-3457f43b91c1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002435.3(MPI):c.1193T>C (p.Ile398Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7662666"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/2bb17322-807e-4464-ac48-5d93eec18a6c","type":"EvidenceLine","dc:description":"NMD not expected","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2bb17322-807e-4464-ac48-5d93eec18a6c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33098580","allele":{"id":"https://genegraph.clinicalgenome.org/r/5ac9134a-13f9-4886-9a75-6609ca5b3e0a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002435.3(MPI):c.973del (p.Leu325SerfsTer24)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2695195445"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f50493b8-3463-4db8-b2de-decc03c42d54","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33098580","rdfs:label":"Proband G","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":2,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/5ac9134a-13f9-4886-9a75-6609ca5b3e0a"},{"id":"https://genegraph.clinicalgenome.org/r/cf2723e0-24bb-462a-a11c-3457f43b91c1"}],"phenotypeFreeText":"PMI activity absent in leukocytes, abnormal CDG-I glycosylation pattern of serum glycoproteins","phenotypes":["obo:HP_0001903","obo:HP_0002243","obo:HP_0002014","obo:HP_0001744","obo:HP_0002240"],"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/62a29060-c957-4b0c-a329-3784857c8043_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/2bb17322-807e-4464-ac48-5d93eec18a6c_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/f864d8bd-318a-480d-b6ea-cc4eef4b4041_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/76ef1061-2456-4685-8da9-17ecaa729f34","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/76ef1061-2456-4685-8da9-17ecaa729f34_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33204592","allele":{"id":"https://genegraph.clinicalgenome.org/r/cf2723e0-24bb-462a-a11c-3457f43b91c1"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/b4c464fb-2e0f-45d3-beba-a1d1ceb1261a","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b4c464fb-2e0f-45d3-beba-a1d1ceb1261a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33204592","allele":{"id":"https://genegraph.clinicalgenome.org/r/9d885e59-e316-4823-8896-f4416e2e7434","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002435.3(MPI):c.884G>A (p.Arg295His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA257213"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/f864d8bd-318a-480d-b6ea-cc4eef4b4041","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33204592","rdfs:label":"CDG-002","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":14,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/9d885e59-e316-4823-8896-f4416e2e7434"},{"id":"https://genegraph.clinicalgenome.org/r/cf2723e0-24bb-462a-a11c-3457f43b91c1"}],"phenotypeFreeText":"Prothrombin activity was 77% and ATIII activity was 56%. Type ITIEF pattern.","phenotypes":["obo:HP_0002910","obo:HP_0031964","obo:HP_0004840","obo:HP_0001541","obo:HP_0001433","obo:HP_0001974","obo:HP_0002243","obo:HP_0031956"],"previousTesting":false,"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/b4c464fb-2e0f-45d3-beba-a1d1ceb1261a_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/76ef1061-2456-4685-8da9-17ecaa729f34_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/ab6dbcc6-df52-48bc-b4c5-16cd636c809f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8b91b881-81f1-46f1-b76c-cf23d09da22e","type":"EvidenceLine","dc:description":"Confirmed phosphomannose isomerase deficiency in leukocytes, fibroblasts, or liver tissue of this patient","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8b91b881-81f1-46f1-b76c-cf23d09da22e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10980531","allele":{"id":"https://genegraph.clinicalgenome.org/r/72197caf-df41-49c3-ab61-cfd2925f78b5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002435.3(MPI):c.391G>A (p.Asp131Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7662430"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/ab6dbcc6-df52-48bc-b4c5-16cd636c809f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10980531","rdfs:label":"Patient C","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"allele":{"id":"https://genegraph.clinicalgenome.org/r/72197caf-df41-49c3-ab61-cfd2925f78b5"},"detectionMethod":"Sanger/PCR of coding region of MPI","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypeFreeText":"Poor feeding, failure to thrive, mild developmental delay(6mo); hepatomegaly, transient increase of alanine aminotransferase[887 IU/I[normal<40 IU/I]], congenital hepatic fibrosis, fibrous expansion of portal areas, mildly dilated ductal structures, severe diarrhea and vomiting episodes, low serum albumin[18g/l[normal36-51 g/l), bowel villous atrophy, crypt hyperplasia, no dilated lacteals, hypoglycemia, hyperinsulinism, decreased antithrombin III and protein C, inverted nipples, fat pads on chin and thighs, CDGS type 1 pattern, olivopontocerebellar degeneration(9mo)","phenotypes":["obo:HP_0000842","obo:HP_0002240","obo:HP_0002014","obo:HP_0002572","obo:HP_0011342","obo:HP_0001943","obo:HP_0011968","obo:HP_0003642","obo:HP_0003186","obo:HP_0003073","obo:HP_0002612","obo:HP_0001976","obo:HP_0001508","obo:HP_0011473","obo:HP_0002542"],"previousTesting":true,"previousTestingDescription":"Galactosaemia and hereditary fructose intolerance were excluded. Phosphomannomutase activity normal, phosphomannose isomerase 30% of normal. No serological\nevidence of coeliac disease","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/8b91b881-81f1-46f1-b76c-cf23d09da22e_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/ba92d7e3-3efe-442e-8f5e-6b3e25678f8c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2644e5d0-8b1a-4c34-9456-1862e7ccb128","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2644e5d0-8b1a-4c34-9456-1862e7ccb128_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9525984","allele":{"id":"https://genegraph.clinicalgenome.org/r/c82a923e-296a-41bf-832e-282fe4ad9bee","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002435.3(MPI):c.166dup (p.Arg56ProfsTer8)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/188967"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/1076f9b8-8e7a-4091-a4b8-99a163fb9c48","type":"EvidenceLine","dc:description":"Functional evidence to support pathogenicity.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1076f9b8-8e7a-4091-a4b8-99a163fb9c48_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the variant in COS-7 cells showed significantly reduced enzymatic activity compared to wt (Table IV). Additional functional evidence in PMID: 9525984, 24421398.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1076f9b8-8e7a-4091-a4b8-99a163fb9c48_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9525984","allele":{"id":"https://genegraph.clinicalgenome.org/r/88de57ce-de4b-4f12-b671-d38f2c0f2285","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002435.3(MPI):c.656G>A (p.Arg219Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA257210"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ba92d7e3-3efe-442e-8f5e-6b3e25678f8c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9525984","rdfs:label":"Index","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":11,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/88de57ce-de4b-4f12-b671-d38f2c0f2285"},{"id":"https://genegraph.clinicalgenome.org/r/c82a923e-296a-41bf-832e-282fe4ad9bee"}],"detectionMethod":"Coding region and exon/intron junctions of MPI gene amplified from genomic DNA and sequenced.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Diarrhea,vomiting (11mo); protein-losing enteropathy in following years; lysosomal inclusion bodies, dilated rought ER with prominent tubular bundles on small bowel biopsy; recurrent thrombotic events at variable locations, several episodes of severe life-threatening GI hemorrhage(6yo). ","phenotypes":["obo:HP_0002013","obo:HP_0002243","obo:HP_0003642","obo:HP_0002239","obo:HP_0002014","obo:HP_0004419"],"previousTesting":true,"previousTestingDescription":"Isoelectric focusing detected hypoglycosylation pattern of CDGS type Ia, confirmed with SDS-PAGE. Metabolic results: PMI activity 3.3% of normal, only transported 15% of mannose compared to WT 90%, 16x lower Vmax for PMI at the same Km for mannose. Laboratory diagnostics repeatedly revealed severe hypoproteinemia, anemia, and markedly reduced antithrombin III (AT III) levels (10–30%).","secondTestingMethod":"PCR","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/2644e5d0-8b1a-4c34-9456-1862e7ccb128_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/1076f9b8-8e7a-4091-a4b8-99a163fb9c48_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/a3dde1eb-170e-42e8-85c6-19a654b88681_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/92d2413c-fe7d-442d-bf24-e9c0e8f6b6ae","type":"EvidenceLine","dc:description":"This variant disrupts the splice donor site but can be left shuffled into the exon (c.840_842del) to preserve the splice site and create an in-frame deletion. ","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/92d2413c-fe7d-442d-bf24-e9c0e8f6b6ae_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33098580","allele":{"id":"https://genegraph.clinicalgenome.org/r/143b5f3e-7b2d-4ca1-be2c-f28c9871798f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.74896324_74896326del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA619413160"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/eaa5d3d8-a041-45fd-8126-9409eb951b84","type":"EvidenceLine","dc:description":"Low MPI activity in patient cells.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eaa5d3d8-a041-45fd-8126-9409eb951b84_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33098580","allele":{"id":"https://genegraph.clinicalgenome.org/r/77b978b4-7ab9-4b85-8dd8-c4e982d1cdc2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002435.3(MPI):c.466G>A (p.Glu156Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA393173678"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a3dde1eb-170e-42e8-85c6-19a654b88681","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33098580","rdfs:label":"Proband A","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/77b978b4-7ab9-4b85-8dd8-c4e982d1cdc2"},{"id":"https://genegraph.clinicalgenome.org/r/143b5f3e-7b2d-4ca1-be2c-f28c9871798f"}],"phenotypeFreeText":"PMI activity in leukocytes was 1.2 U/g (ref >5.5), abnormal CDG-I glycosylation pattern of serum glycoproteins.","phenotypes":["obo:HP_0002014","obo:HP_0002240","obo:HP_0001943"],"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/92d2413c-fe7d-442d-bf24-e9c0e8f6b6ae_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/eaa5d3d8-a041-45fd-8126-9409eb951b84_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/bce98ecb-4a6f-4200-8451-a487814e1e19_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/da6ab184-5326-4f8e-abcf-9059c8f68cf6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/da6ab184-5326-4f8e-abcf-9059c8f68cf6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"When expressed in an mpi-null yeast strain, the variant showed 0.6% residual activity (PMID: 24474243)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/da6ab184-5326-4f8e-abcf-9059c8f68cf6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9585601","allele":{"id":"https://genegraph.clinicalgenome.org/r/42029a59-ee34-40f9-ba07-0512a08b651a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002435.3(MPI):c.305C>T (p.Ser102Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/14346"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/2cdb8154-2883-4a56-9720-a9d8e390448f","type":"EvidenceLine","dc:description":"High residual activity in yeast cells.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2cdb8154-2883-4a56-9720-a9d8e390448f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"When expressed in an mpi-null yeast strain, the variant showed 82% residual activity (PMID: 24474243),","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2cdb8154-2883-4a56-9720-a9d8e390448f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9585601","allele":{"id":"https://genegraph.clinicalgenome.org/r/5db90ba0-9063-4ed4-a7f2-20566c884ee5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002435.3(MPI):c.413T>C (p.Met138Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/14347"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/bce98ecb-4a6f-4200-8451-a487814e1e19","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9585601","rdfs:label":"Patient A","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":4,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/42029a59-ee34-40f9-ba07-0512a08b651a"},{"id":"https://genegraph.clinicalgenome.org/r/5db90ba0-9063-4ed4-a7f2-20566c884ee5"}],"ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Chronic diarrhea(3mo); hypoglycemia, convulsions, coma, apnea, liver 6cm below margin and firm, portal space fibrosis, microvesicular steatosis(5.5mo); generalized edema, hypoalbuminemia, moderate motor delay, slightly increased liver bilirubin[50mM] and glutamate-oxaloacetate transaminase[82U/liter], decreased IgG[2.6g/liter]] and IgA[0.32g/liter], prothrombin time[63%],factor XI[20%], antithrombin III[45%], protein C[29%], total protein S[51%], intermittent slight proteinuria, moderate hypoglycemia, type 1 CDG, fragile intestinal mucosa with easy bleeding, partial villous atrophy with hypercelularity, rare/discrete lymphangiectasias, congenital hepatic fibrosis, stellate fibrosis of portal spaces,proliferation of biliary canaliculi w/o inflammation or hepatocyte alteration, renal hyperechogenicity(10mo), large abdomen with pronounced collateral circulation, disseminated angiomas, nasogastric tube feeding->gastrostomy(26mo), protein-losing enteropathy(2yo)","phenotypes":["obo:HP_0040288","obo:HP_0002104","obo:HP_0002197","obo:HP_0002612","obo:HP_0006580","obo:HP_0001929","obo:HP_0002593","obo:HP_0003573","obo:HP_0005543","obo:HP_0003073","obo:HP_0001943","obo:HP_0011473","obo:HP_0000093","obo:HP_0001414","obo:HP_0008151","obo:HP_0001270","obo:HP_0004315","obo:HP_0001408","obo:HP_0002243","obo:HP_0002028","obo:HP_0002720","obo:HP_0001259","obo:HP_0007430","obo:HP_0001976","obo:HP_0003642"],"previousTesting":true,"previousTestingDescription":"Phosphomannomutase activty normal, radiological exam showed malabsorption and flocculation of control substance in intestines, normal sweat test and disaccharidase activities","secondTestingMethod":"PCR","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/da6ab184-5326-4f8e-abcf-9059c8f68cf6_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/2cdb8154-2883-4a56-9720-a9d8e390448f_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.6},{"id":"https://genegraph.clinicalgenome.org/r/90d6b576-64ed-4e59-a711-f040cad88070_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1db0ed73-aed5-4620-820b-e9aeef17c24a","type":"EvidenceLine","dc:description":"no PMI activity detected in patient fibroblasts, low activity in patient mononuclear cells","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1db0ed73-aed5-4620-820b-e9aeef17c24a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17945525","allele":{"id":"https://genegraph.clinicalgenome.org/r/9d885e59-e316-4823-8896-f4416e2e7434"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/90d6b576-64ed-4e59-a711-f040cad88070","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17945525","rdfs:label":"P2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/9d885e59-e316-4823-8896-f4416e2e7434"},"detectionMethod":"not sepcificied","ethnicity":{"id":"cg:UnknownEthnicity"},"phenotypeFreeText":"Vomiting, diarrhea, protein-losing enteropathy, hypoalbuminemia, edmea, hyperinsulinism, symptomic hypoglycemia, large firm liver(2mo). Dystrophic and dilated bile ducts, prominent portal fibrosis(2yo).","phenotypes":["obo:HP_0002014","obo:HP_0001943","obo:HP_0002240","obo:HP_0003073","obo:HP_0002013","obo:HP_0000842","obo:HP_0000969","obo:HP_0002243"],"previousTesting":true,"previousTestingDescription":"All known causes of liver disease excluded. Metabolic tests: AST 700 IU/l, ALT, 300 IU/l, normal bilirubin and GGT, prothrombin time 70%, normal factor V, decreased factor XI, antithrombin III, protein C&S(5-33%). Undetectable PMI activity in fibroblast and low in blood mononuclear cells.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/1db0ed73-aed5-4620-820b-e9aeef17c24a_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/e810bd02-4817-4125-8e5f-87a8b9bdcc61_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2f5fb0b4-6c0c-4cb8-8565-c74bf6058d9f","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2f5fb0b4-6c0c-4cb8-8565-c74bf6058d9f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10980531","allele":{"id":"https://genegraph.clinicalgenome.org/r/c8c9c4e5-9843-4724-9856-e62e87546022","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002435.3(MPI):c.1253G>A (p.Arg418His)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/218095"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/ba08e4ab-17b0-45fe-96d7-9595eaa07096","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ba08e4ab-17b0-45fe-96d7-9595eaa07096_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10980531","allele":{"id":"https://genegraph.clinicalgenome.org/r/0f095391-a9f8-4a63-8976-af4f97eab377","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002435.3(MPI):c.488-1G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/371556"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e810bd02-4817-4125-8e5f-87a8b9bdcc61","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10980531","rdfs:label":"Patient D","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":2,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/c8c9c4e5-9843-4724-9856-e62e87546022"},{"id":"https://genegraph.clinicalgenome.org/r/0f095391-a9f8-4a63-8976-af4f97eab377"}],"detectionMethod":"Coding region and exon/intron junctions of MPI gene amplified from genomic DNA and sequenced.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Diarrhea, slightly hypotonic, sleepy during feedings, pattern of frequent small-volume feedings, growth and development normal(first weeks); seizures(5mo); prolonged vomitting episode, hypoglycemia[1.49 mmol/L [27 mg/dL]], dicarboxylic aciduria without ketones, delayed bone age(8mo); 2 hair whorls, somehwat small forehead, full cheeks, no dysmorphic facies, inverted nipples, fusiform proximal phalanges, slightly elevated insulin(11mo); during infection-prolonged seizures, decreased coagulation factors[II, VII, VIII, IX, and XI], decreased antithrombin III and total protein S activity,protein-losing enteropathy, low serum protein levels, generalized edema, elevated AT[30x normal],hemoglobin[8.1g/dL], hematocrit[25.1%], erythrocytes[3.44x10(12)/L], mean corpuscular volume[72.9fL], liver biopsy had feature of hepatic fibrosis, low total thyroxine, type 1 CDGS on transferrin IEF(2yo)","phenotypes":["obo:HP_0000350","obo:HP_0002243","obo:HP_0002329","obo:HP_0001943","obo:HP_0003186","obo:HP_0007430","obo:HP_0010813","obo:HP_0001319","obo:HP_0003075","obo:HP_0001976","obo:HP_0000293","obo:HP_0002014","obo:HP_0001250","obo:HP_0003642","obo:HP_0002750","obo:HP_0003215"],"previousTesting":true,"previousTestingDescription":"Negative for variants in sulfonylurea receptor gene. Homocysteine, mutation analysis for factor V Leiden, upper gastrointestinal endoscopy, flexible sigmoidoscopy, and biopsy specimens of small bowel, sigmoid colon, and rectum,  free thyroxin and thyroid-stimulating hormone levels  were normal. Also normal growth hormone, ketotic response, normal insulin, blunted response to glucagon, and undersialylation of transferrin. Excluded fructosemia, disorders of copper metabolism, glycogen storage disorders, glycerol kinase deficiency, peroxisome disorder, mitochondrial DNA abnormality, biotinidase deficiency, α1-antitrypsin deficiency, and defects in β-oxidation of fatty acids.","secondTestingMethod":"PCR","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/2f5fb0b4-6c0c-4cb8-8565-c74bf6058d9f_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/ba08e4ab-17b0-45fe-96d7-9595eaa07096_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/03af9bd5-4b45-47ce-8bb1-80addd1a812a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1c8946b6-c29f-44e8-852d-ca5943fba468","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1c8946b6-c29f-44e8-852d-ca5943fba468_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the variant in COS-7 cells showed significantly reduced enzymatic activity compared to wt (Table IV). Additional functional evidence in PMID: 9525984, 24421398.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1c8946b6-c29f-44e8-852d-ca5943fba468_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33204592","allele":{"id":"https://genegraph.clinicalgenome.org/r/88de57ce-de4b-4f12-b671-d38f2c0f2285"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/cb1eb8dd-5b23-4d37-9213-7e6610d92ba0","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cb1eb8dd-5b23-4d37-9213-7e6610d92ba0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33204592","allele":{"id":"https://genegraph.clinicalgenome.org/r/cb01dc96-1fe3-421d-88c9-ccd5a43e3f03","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002435.3(MPI):c.487A>T (p.Lys163Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA393173833"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/03af9bd5-4b45-47ce-8bb1-80addd1a812a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33204592","rdfs:label":"CDG-001","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/cb01dc96-1fe3-421d-88c9-ccd5a43e3f03"},{"id":"https://genegraph.clinicalgenome.org/r/88de57ce-de4b-4f12-b671-d38f2c0f2285"}],"phenotypeFreeText":"TIEF revealed elevation of disialo- andasialo-transferrin","phenotypes":["obo:HP_0012724","obo:HP_0031956","obo:HP_0003073","obo:HP_0004840","obo:HP_0001974","obo:HP_0001744","obo:HP_0002014","obo:HP_0002240"],"previousTesting":false,"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/1c8946b6-c29f-44e8-852d-ca5943fba468_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/cb1eb8dd-5b23-4d37-9213-7e6610d92ba0_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/a6c880b8-c9fc-453b-8975-236a97047192_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ee8f0fc-d0ee-4afe-b167-f06f4b93a053_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals to count","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11350186","rdfs:label":"Westphal_Siblings","estimatedLodScore":0.73,"family":{"id":"https://genegraph.clinicalgenome.org/r/2ee8f0fc-d0ee-4afe-b167-f06f4b93a053","type":"Family","rdfs:label":"Westphal_Siblings","ethnicity":{"id":"cg:UnknownEthnicity"},"member":{"id":"https://genegraph.clinicalgenome.org/r/deb4d5fa-1519-4b11-9f42-8958e99946b3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11350186","rdfs:label":"Patient 2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":33,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/e5a78f22-5ef9-48c1-89a7-1787acdc58bc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002435.3(MPI):c.419T>C (p.Ile140Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7662435"}},{"id":"https://genegraph.clinicalgenome.org/r/88de57ce-de4b-4f12-b671-d38f2c0f2285"}],"detectionMethod":"RT-PCR and direct sequencing of MPI exons","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"PCR","phenotypeFreeText":"Fever, vomiting, diarrhea, hepatomegaly, deep venous thrombosis, tenderness, cyanosis, edema of left leg(2.5 and 3.5yo), Type 1 transferrin IEF (33yo)","phenotypes":["obo:HP_0000961","obo:HP_0010741","obo:HP_0003642","obo:HP_0002625","obo:HP_0001976"],"previousTesting":true,"previousTestingDescription":"Liver function, faecal fat excretion, enzyme contents of duodenal juice and specific allergy tests negative. Xylose-, glucose-, lactose-, and sucrose-absorption tests normal. Reduced serum protein(patient 1: 28-62g/l, patient 2: 25-47g/l), reduced albumin fraction(P1: 20-32g/l, P2: 15-27g/l). Save for antithrombin III, coagulation tests were normal.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/dc773f3f-f706-459e-8c10-d903c8b4be80_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11350186","allele":{"id":"https://genegraph.clinicalgenome.org/r/e5a78f22-5ef9-48c1-89a7-1787acdc58bc"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/1878fb83-0020-4960-b16d-3861d6ba3bcd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11350186","allele":{"id":"https://genegraph.clinicalgenome.org/r/88de57ce-de4b-4f12-b671-d38f2c0f2285"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]}},"phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0001945","obo:HP_0004936","obo:HP_0000969","obo:HP_0002243","obo:HP_0025283","obo:HP_0001395","obo:HP_0002240","obo:HP_0002013","obo:HP_0002014"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/deb4d5fa-1519-4b11-9f42-8958e99946b3"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/deb4d5fa-1519-4b11-9f42-8958e99946b3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1878fb83-0020-4960-b16d-3861d6ba3bcd","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1878fb83-0020-4960-b16d-3861d6ba3bcd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the variant in COS-7 cells showed significantly reduced enzymatic activity compared to wt (Table IV). Additional functional evidence in PMID: 9525984, 24421398.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1878fb83-0020-4960-b16d-3861d6ba3bcd_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/dc773f3f-f706-459e-8c10-d903c8b4be80","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dc773f3f-f706-459e-8c10-d903c8b4be80_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/deb4d5fa-1519-4b11-9f42-8958e99946b3"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.6}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/a6c880b8-c9fc-453b-8975-236a97047192_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a6c880b8-c9fc-453b-8975-236a97047192_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bd47ef89-d037-4cfd-82d6-9ed1623bfe79","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c9125e34-fdc4-4087-8c0c-34cc822b3adb","type":"Finding","dc:description":"Like other type I CDGs, there is a dramatic reduction of ICAM-1 in CDG-Ib patient fibroblasts (He et al. 2012), which is involved in the innate immune response. This reduction in ICAM-1 could explain the recurrent infections in CDG patients. The authors used intraperitoneal injection of zymosan to induce an inflammatory response and found decreased neutrophil extravasation compared with control mice. Since mannose supplementation in CDG patients improves glycosylation, the authors provided the MPI-deficient mice with mannose for 7 days which restored ICAM-1 expression and enhanced migration of neutrophils during acute inflammation. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24474243","rdfs:label":"He 2014 Mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/e7ef730c-2efd-4a2d-88aa-b3eb6ff6dbae","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7ea5d32a-ac3c-491c-b4ba-bb00a6096da1","type":"Finding","dc:description":"The function of MPI in N-glycosylation is to produce mannose-6-phosphate which is then converted to mannose-1-phosphate by PMM2, and subsequently to GDP-mannose, which is used as the substrate for generating the mature lipid-linked oligosaccharide (LLO). Both mature LLO and mannose-6-phosphate levels were decreased in mpi morphants (47 and 41% respectively). Mpi morphants also had 47% decrease in N-linked glycans, consistent with hypoglycosylated serum glycoproteins in MPI-CDG patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22899857","rdfs:label":"Chu 2013 Zebrafish","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/a6c880b8-c9fc-453b-8975-236a97047192_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c9f32e96-4391-41c1-948a-c70ef1531546","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b4f38fe9-d14e-4918-92bd-80d127063a4c","type":"FunctionalAlteration","dc:description":"Proteins with unoccupied glycosylation sites are often degraded by glycoprotein quality control mechanisms and fail to reach the plasma membrane. Such proteins might show lower expression in glycosylation-deficient cells and could be potential markers of hypoglycosylation. ICAM-1 is a known marker of hypoglycosylation. In patient cells, ICAM-1 was significantly reduced compared to normal controls. Similar results were seen in patients with PMM2 mutations, which is the most common cause of CDG type 1.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22496445","rdfs:label":"Hypoglycosylation in CDG patient cells"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/a6c880b8-c9fc-453b-8975-236a97047192_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c8d107d4-30d0-4857-9a49-7a1ba697496d","type":"EvidenceLine","dc:description":"Studies have proved that mannose therapy improved the general condition and digestive symptoms in all reported patients but one, whereas the first patients with severe clinical presentations who received no mannose treatment died (PMID: 19101627). There is a clear link between the function of MPI and the phenotype of patients with CDG type Ib.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef475547-58e8-44fc-8e7d-8262314ca0a7","type":"Finding","dc:description":"Previous studies suggested that mannose could correct abnormal glycosylation. Mannose therapy was initiated and followed up for 11 months in a proband. GI bleeding and chronic diarrhea disappear within the first few weeks. Total serum protein and antithrombin III rose to normal levels. A profound decrease in abnormal isoforms and a shift towards a normal pattern of serum transferring was observed.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9525984","rdfs:label":"Mannose Incorporation in CDGs","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":7335,"specifiedBy":"GeneValidityCriteria10","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/HsyjwDQOAqw","type":"GeneValidityProposition","disease":"obo:MONDO_0011257","gene":"hgnc:7216","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_a6c880b8-c9fc-453b-8975-236a97047192-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}